icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 study
 
 
  Reported by Jules Levin AASLD Nov 5-9 2011 SF
 
Stefan Zeuzem,1 Vincent Soriano,2 Tarik Asselah,3 Jean-Pierre Bronowicki,4 Emanoil Ceausu,5 Ansgar W. Lohse,6 Adrian Streinu-Cercel,7 Liliana Preotescu,7 Joseph Moussalli,8 Beat Mullhaupt,9 Marcus Schuchmann,10 Marc Bourliere,11 Filipe Calinas,12 Maria Buti,13 Stuart K. Roberts,14 Edward J. Gane,15 Jerry O. Stern,16 Gerhard Nehmiz,17 Helge Bonaventura,17 Wulf O. Boecher,17 Federico J. Mensa16 1Klinikum der J.W. Goethe-Universität, Frankfurt, Germany; 2Hospital Carlos III, Madrid, Spain; 3Hôpital Beaujon, Clichy Cedex, France; 4Hopital de Brabois, Vandoeuvre Cedex, France; 5"Dr Victor Babes" Hospital of Infectious Diseases, Bucharest, Romania; 6Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 7"Prof. Dr. Matei Bals" Institute of Infectious Diseases, Bucharest, Romania; 8Hopital Pitie Salpetriere, Paris, France; 9Universitatsspital Zurich, Zürich, Switzerland; 10Johannes Gutenberg Universität, Mainz, Germany; 11Hopital Saint Joseph, Marseille Cedex, France; 12Centro Hospitalar de Lisboa Central, Lisbon, Portugal; 13Hospital Vall d'Hebron, Barcelona, Spain; 14Alfred Hospital, Melbourne, Victoria, Australia; 15Auckland Clinical Studies, Auckland, New Zealand; 16Clinical Research - Virology, Boehringer Ingelheim Pharm. Inc., Ridgefield, CT, USA; 17Department of Clinical Research, Boehringer Ingelheim GmbH, Biberach, Germany

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif